Speakers

Sort by
Newest
Trending
1-10 of 10
Filter
Jokūbas Žiburkus
CEO and Co-Founder at Adendox
allosteric modulator, allosteric regulation, cannabidiol, cannabinoid, cannabinoid receptor, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabis, cannabis indica, cytokine, endocannabinoid system, glutamate (neurotransmitter), hashish, hippocampus, inflammation, medical cannabis, nervous system, neuron, neuroprotection, neuroscience, receptor antagonist, synapse, tetrahydrocannabinol, tetrahydrocannabinolic acid
Adam Abodeely
Board Certified Surgeon & CEO-Founder at ReserveMD
adoption, allosteric modulator, alternative medicine, anesthesia, anticoagulant, antihypertensive drug, appetite, audit, background check, bank, benzodiazepine, best practice, bioavailability, bleeding, bloating, blood sugar level, board certification, brand, breathing, budtender, c-reactive protein, cancer, cannabidiol, cannabinoid, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabinol, cannabis, cannabis (drug), cannabis sativa, carbohydrate, central processing unit, charlotte's web (cannabis), chemotherapy, chemotherapy-induced nausea and vomiting, clinical trial, commerce clause, controlled substances act, craft brewery and microbrewery, crohn's disease, dementia, depression (mood), diarrhea, dietary supplement, disease, dose (biochemistry), drug, drug development, drug overdose, due diligence, edema, emergency department, endocannabinoid system, entourage effect, fda food safety modernization act, fda warning letter, fibromyalgia, flavonoid, food, food and drug administration, food safety, foodborne illness, gastrointestinal disease, gastroparesis, general surgery, good manufacturing practice, gut–brain axis, headache, heartburn, hemp, hemp oil, heroin, homeostasis, ibuprofen, ileostomy, immune system, indication (medicine), inflammation, inflammatory bowel disease, inhaler, intestinal permeability, iso 9000, lemon, lobbying, lung volumes, macrophage, medical cannabis, medical prescription, medication, mind, morphine, nanotechnology, nausea, neurology, neuron, neurosurgery, neurotransmitter, nicotine, nsf international, nutraceutical, opiate, opioid, opioid epidemic in the united states, opioid overdose, over-the-counter drug, oxycodone, oxycodone/paracetamol, pain, pain management, pathology, patient, personalized medicine, pharmaceutical industry, pharmacogenomics, pharmacokinetics, pharmacology, pharmacy, physician, placebo, placebo-controlled study, polypharmacy, prescription drug, psychoactive drug, quality management system, reason, regulatory compliance, rhabdomyosarcoma, risk, route of administration, safety, scientific method, sensitivity and specificity, serotonin, serotonin syndrome, signal transduction, spasticities, stress (biology), surgery, synthetic cannabinoids, terminal illness, terpene, tetrahydrocannabinol, tetrahydrocannabinol acid, therapeutic index, therapy, toxicity, ulcerative colitis, understanding, verification and validation, warfarin, water
Sean Colvin
Senior Scientist at TreeHouse Biotech
alternative medicine, cannabidiol, cannabinoid, cannabinoid receptor, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabinol, cannabis (drug), crohn's disease, drink, endocannabinoid system, entourage effect, gpr55, hash oil, immune system, immunodeficiency, liquor, moonshine, neuron, pharmaceutical industry, pharmacology, prohibition, receptor (biochemistry), tetrahydrocannabinol, weight training
Tyrell Towle
Director of Chemistry at MedPharm Holdings
alternative medicine, cannabidiol, cannabinoid, cannabinoid receptor, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabinol, cannabis (drug), crohn's disease, drink, endocannabinoid system, entourage effect, gpr55, hash oil, immune system, immunodeficiency, liquor, moonshine, neuron, pharmaceutical industry, pharmacology, prohibition, receptor (biochemistry), tetrahydrocannabinol, weight training
Julie P. Fry
Cannabis Industry Consultant
alternative medicine, cannabidiol, cannabinoid, cannabinoid receptor, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabinol, cannabis (drug), crohn's disease, drink, endocannabinoid system, entourage effect, gpr55, hash oil, immune system, immunodeficiency, liquor, moonshine, neuron, pharmaceutical industry, pharmacology, prohibition, receptor (biochemistry), tetrahydrocannabinol, weight training
Joshua Jones
Founder at Jonesing Labs
alternative medicine, cannabidiol, cannabinoid, cannabinoid receptor, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabinol, cannabis (drug), crohn's disease, drink, endocannabinoid system, entourage effect, gpr55, hash oil, immune system, immunodeficiency, liquor, moonshine, neuron, pharmaceutical industry, pharmacology, prohibition, receptor (biochemistry), tetrahydrocannabinol, weight training
Anna Schwabe
Cannabis Geneticist and Research Coordinator at Mile High Labs
alternative medicine, cannabidiol, cannabinoid, cannabinoid receptor, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabinol, cannabis (drug), crohn's disease, drink, endocannabinoid system, entourage effect, gpr55, hash oil, immune system, immunodeficiency, liquor, moonshine, neuron, pharmaceutical industry, pharmacology, prohibition, receptor (biochemistry), tetrahydrocannabinol, weight training
David Ostrow
Director at David Ostrow & Associates
allosteric regulation, alzheimer's disease, anxiolytic, brain, cannabidiol, cannabinoid, cannabinoid receptor type 1, cannabinoid receptor type 2, cell nucleus, channel blocker, endocannabinoid system, gene expression, hiv/aids, homeostasis, ligand (biochemistry), medical cannabis, medication, nervous system, neuron, organism, pharmacology, receptor antagonist, relapse, stimulus (physiology), tetrahydrocannabinol
Hervé Damas
Founder & CEO at Dr. Damas Wellness
action potential, allosteric modulator, autoimmune disease, axon, axon terminal, cannabinoid, cannabinoid receptor, cannabinoid receptor type 1, cannabinoid receptor type 1 can, chemical synapse, depolarization, depressant, dopamine, entourage effect, epilepsy, epileptic seizure, gamma-aminobutyric acid, glutamic acid, monosodium glutamate, neuron, neurotransmitter, receptor antagonist, reuptake, selective serotonin reuptake inhibitor, synapse, tetrahydrocannabinol
Carter Baird
R&D Laboratory Technician at United Cannabis Corporation
absorption (pharmacology), alternative medicine, bioavailability, blood sugar level, cannabidiol, cannabinoid, cannabinoid receptor, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabinol, cannabis, cannabis (drug), chemist, concussion, crohn's disease, cytochrome p450, dose (biochemistry), drink, emotion, endocannabinoid system, entourage effect, enzyme, gpr55, hash oil, immune system, immunodeficiency, liposome, liquor, memory, micelle, milk, moonshine, nanotechnology, neuroimaging, neuron, pharmaceutical industry, pharmacokinetics, pharmacology, prohibition, receptor (biochemistry), receptor antagonist, surfactant, tetrahydrocannabinol, weight training
1